

1 **Title:**

2

3 **Analysis of differentially methylated regions in primates and non-primates**

4 **provides support for the evolutionary hypothesis of schizophrenia**

5

6 Niladri Banerjee^{a,b}, Tatiana Polushina^{a,b}, Francesco Bettella^{c,d},

7 Vidar M. Steen^{a,b}, Ole A. Andreassen^{c,d}, Stephanie Le Hellard^{a,b}

8

9 a. NORMENT - K.G. Jebsen Center for Psychosis Research, Department of Clinical

10 Science, University of Bergen, Bergen, Norway

11 b. Dr. Einar Martens Research Group for Biological Psychiatry, Department of

12 Medical Genetics, Haukeland University Hospital, Bergen, Norway

13 c. NORMENT - K.G. Jebsen Center for Psychosis Research, Institute of Clinical

14 Medicine, University of Oslo, Oslo, Norway

15 d. NORMENT - K.G. Jebsen Centre, Division of Mental Health and Addiction, Oslo

16 University Hospital, Oslo, Norway

17

18 **Correspondence to:** Prof. Stéphanie Le Hellard, Department of Clinical Medicine,

19 Laboratory Building, Haukeland University Hospital, N-5021 Bergen, Norway.

20 **Telephone:** +47-55 97 53 37

21 **Fax:** +47-55 97 54 79

22 **Email:** stephanie.hellard@uib.no

23

24 **Authors' email addresses**

25 Niladri Banerjee

niladri.banerjee@uib.no

26	Tatiana Polushina	tatiana.polushina@uib.no
27	Francesco Bettella	francesco.bettella@medisin.uio.no
28	Vidar M. Steen	vidar.martin.steen@helse-bergen.no
29	Ole A. Andreassen	o.a.andreassen@medisin.uio.no
30	Stéphanie Le Hellard	stephanie.hellard@uib.no
31		
32		

33 **Abstract**

34

35 Introduction: The persistence of schizophrenia in human populations separated by
36 geography and time led to the evolutionary hypothesis that proposes schizophrenia as
37 a by-product of the higher cognitive abilities of modern humans. To explore this
38 hypothesis, we used here an evolutionary epigenetics approach building on
39 differentially methylated regions (DMRs) of the genome.

40 Methods: We implemented a polygenic enrichment testing pipeline using the
41 summary statistics of genome-wide association studies (GWAS) of schizophrenia and
42 12 other phenotypes. We investigated the enrichment of association of these traits
43 across genomic regions with variable methylation between modern humans and great
44 apes (orangutans, chimpanzees and gorillas; primate DMRs) and between modern
45 humans and recently extinct hominids (Neanderthals and Denisovans; non-primate
46 DMRs).

47 Results: Regions that are hypo-methylated in humans compared to great apes show
48 enrichment of association with schizophrenia only if the major histocompatibility
49 complex (MHC) region is included. With the MHC region removed from the analysis,
50 only a modest enrichment for SNPs of low effect persists. The INRICH pipeline
51 confirms this finding after rigorous permutation and bootstrapping procedures.

52

53 Conclusion: The analyses of regions with differential methylation changes in humans
54 and great apes do not provide compelling evidence of enrichment of association with
55 schizophrenia, in contrast to our previous findings on more recent methylation
56 differences between modern humans, Neanderthals and Denisovans. Our results

57 further support the evolutionary hypothesis of schizophrenia and indicate that the
58 origin of some of the genetic susceptibility factors of schizophrenia may lie in recent
59 human evolution.

60

61

62 **Key Words:** schizophrenia; evolutionary hypothesis; epigenetics; differentially
63 methylated regions; primates; Neanderthals.

64

65

66

67

68

69

70

71

72 **1. Introduction**

73

74 Schizophrenia is a psychiatric disorder with a prevalence rate of 2.7-8.3/1,000 persons
75 (Messias et al., 2007) and heritability estimated between 60-90% (Cardno et al., 1999;
76 Lichtenstein et al., 2009; Skre et al., 1993; Sullivan et al., 2003). It occurs at quite
77 similar rates across populations worldwide (Ayuso-Mateos, 2002; Brüne, 2004;
78 WHO, 1973) and written records describing its symptoms exist dating back 5,000
79 years (Jeste et al., 1985). This consistent persistence of the disease despite reduced
80 fecundity (Brüne, 2004; Nichols, 2009) and increased mortality is a paradox (Bassett
81 et al., 1996; Brown, 1997; Larson and Nyman, 1973), since the reduced fecundity of
82 patients afflicted with schizophrenia does not appear to eliminate the disease from the
83 population (Power et al., 2013) Part of the reason may be due to afflicted individuals
84 reproducing prior to the onset of the disease (Markow, 2012). Another contributing
85 factor could be that schizophrenia risk variants may have provided an advantage to
86 the kin of the affected by conferring superior creative and intellectual abilities upon
87 them (Kyaga et al., 2011; Nichols, 2009). To explain the constant occurrence of the
88 disease, TJ Crow (Crow, 1997, 1995) proposed the so-called evolutionary hypothesis
89 of schizophrenia, which suggests that the disease is a consequence of human
90 evolution: the higher cognitive abilities of modern-day humans, including language,
91 may predispose to psychiatric illnesses such as schizophrenia (Crow, 2008, 2000,
92 1997).

93

94 In the post-genomic era (Lander et al., 2001; Venter et al., 2001), emerging lines of
95 evidence are lending support to this hypothesis. Crespi et al. (Crespi et al., 2007) were
96 amongst the first to show that genes with evidence of recent positive selection in

97 humans are also implicated more frequently in schizophrenia. More evidence has
98 been provided by studies based on comparative genomics (Pollard et al., 2006;
99 Srinivasan et al., 2015; Xu et al., 2015), a field in which genomes of progressively
100 older species are compared to identify substitutions and mutations that help estimate
101 divergence between the species. For instance, a group of regions defined by negative
102 Neanderthal selective sweep (NSS) scores describe the selective evolution of genomic
103 regions in modern-day humans over Neanderthals (Burbano et al., 2010; Green et al.,
104 2010). These regions were shown by Srinivasan et al. (2015) to be enriched for
105 schizophrenia risk markers, in line with the evolutionary hypothesis of schizophrenia.
106 Other regions known as human accelerated regions (HARs) (Gittelman et al., 2015;
107 Pollard et al., 2006; Xu et al., 2015), first described by Pollard et al. (2006), show
108 accelerated evolution in humans compared to primates or mammals. HARs have also
109 provided some evidence of enrichment of association with schizophrenia (Xu et al.,
110 2015), but these findings may have been driven by a few genes since they were not
111 replicated using a polygenic approach (Srinivasan et al., 2017, 2015) .

112

113 While several studies have looked at the evolution of the genome (Bird et al., 2007;
114 Bush and Lahn, 2008; Gittelman et al., 2015; Paaby and Rockman, 2014; Pollard et
115 al., 2006), there are reports that the epigenome is evolving as well (Gokhman et al.,
116 2014; Hernando-Herraez et al., 2015, 2013; Mendizabal et al., 2014; Molaro et al.,
117 2011). This provides new insights into events leading to the speciation and divergence
118 of modern humans. The epigenome refers to the layer of chemical modifications, such
119 as methylation and histone modifications, to the genome that regulate gene expression
120 (Bernstein et al., 2007; Kundaje et al., 2015; Rivera and Ren, 2013). For instance,
121 Gokhman et al. (2014) compared the methylomes of humans with Neanderthals and

122 Denisovans. They reported that while 97% of the methylome was comparable
123 between humans, Neanderthals and Denisovans, some regions showed differential
124 methylation between the three hominids. Previously (Banerjee et al., 2017), we
125 analysed the differentially methylated regions (DMRs) identified for Neanderthals,
126 Denisovans and modern humans by Gokhman et al. (2014), and found evidence that
127 the regions of the genome with human-specific DMRs harbour relatively more genetic
128 variants associated with schizophrenia than the rest of the genome, i.e. the DMRs
129 were enriched for SCZ markers both at the single-nucleotide polymorphism (SNP)
130 level and at the gene level. These human-specific DMRs thus provide evidence of
131 enrichment of methylation changes in regions harbouring genetic variants associated
132 with schizophrenia, at least since the divergence from Neanderthals and Denisovans
133 (Banerjee et al., 2017).

134

135 Here, we sought to determine if evolutionarily older methylation differences can
136 provide a further timeframe for the origin of schizophrenia risk markers in the human
137 lineage. We asked whether we can find epigenetic evidence that the origin of
138 schizophrenia risk markers predates the origins of the Homo genus, i.e. before the
139 divergence of chimpanzees and humans around 6-8 million years ago (MYA) (Glazko
140 and Nei, 2003; Langergraber et al., 2012). We tested this hypothesis by analysing
141 primate DMRs that trace an evolutionary history of at least 13 million years (Glazko
142 and Nei, 2003; Hasegawa et al., 1985; Rannala and Yang, 2003). We used the same
143 statistical analyses as described by Lee et al. (2012), Schork et al. (2013), and
144 Srinivasan et al. (2015) to test for polygenic enrichment of a set of markers from
145 genome-wide association studies (GWAS). We interrogated regions of the human
146 genome which are hypo- or hyper-methylated in comparison to the corresponding

147 ones in chimpanzees, gorillas and orangutans for enrichment of genetic variants

148 associated with schizophrenia or other human traits.

149

150 **2. Materials and methods**

151

152 *2.1. GWAS data*

153 Summary statistics for thirteen different phenotypes were obtained from their
154 respective published GWAS studies: schizophrenia (SCZ) (Ripke et al., 2014), bipolar
155 disorder (BPD) (Sklar et al., 2011), attention deficit hyperactivity disorder (ADHD)
156 (Demontis et al., 2017), rheumatoid arthritis (RA) (Stahl et al., 2010), blood lipid
157 markers (high density lipoprotein (HDL), low density lipoprotein (LDL), triglycerides
158 (TG), total cholesterol (TC)) (Teslovich et al., 2010), blood pressure (systolic blood
159 pressure (SBP), diastolic blood pressure (DBP)) (Ehret et al., 2011), body mass index
160 (BMI) (Locke et al., 2015), height (Wood et al., 2014) and intelligence (Sniekers et
161 al., 2017). For studies published with hg18 coordinates (BPD, SBP, DBP, HDL, LDL,
162 TG, TC, RA), conversion to hg19 was performed using the command line version of
163 the liftOver tool from the UCSC Genome Browser (Karolchik et al., 2014)
164 (http://hgdownload.cse.ucsc.edu/downloads.html#utilities_downloads). For BMI and
165 height SNPs, the genomic coordinates were obtained by mapping them to the
166 assembly of 1,000 Genomes Project (1KGP) Phase 1 reference panel SNPs (Durbin et
167 al., 2012).

168

169 *2.2. Human hypo- and hyper-methylated regions from primate DMRs*

170 These methylated regions were retrieved from the study by Hernando-Herraez et al.
171 (2015), who identified them by comparing the methylation profile of DNA from
172 peripheral blood samples of orangutans, chimpanzees and gorillas to that of humans.
173 Since the DMRs are determined by comparing humans with other primates, we refer
174 to this set collectively as primate DMRs. Both hypo- and hyper-methylated DMRs

175 from humans were analysed. As these DMRs are identified in the same tissues in all
176 samples, they are considered to represent species-specific methylation differences, not
177 tissue-specific methylation differences (Gokhman et al., 2014). Altogether, the human
178 hypo- and hyper-methylated DMRs can be used to represent an evolutionary course of
179 history spanning from at least 13 MYA (Glazko and Nei, 2003; Langergraber et al.,
180 2012), when orangutans diverged from the common ancestors, to 6 MYA, when the
181 chimpanzees and humans diverged from each other (Glazko and Nei, 2003;
182 Langergraber et al., 2012). Since our interest was in human-specific enrichment, we
183 focused the analyses on human hypo- and hyper-methylated DMRs.

184

185 *2.3. Differentially methylated regions (DMRs) from Neanderthals, Denisovans and* 186 *modern humans*

187 As previously described (Gokhman et al., 2014), these methylated regions have been
188 identified by comparing the methylomes of osteoblasts from modern-day humans
189 with those from Neanderthals and Denisovans. We refer to them in this paper as non-
190 primate DMRs. Gokhman et al. (2014) devised a strategy utilizing information in the
191 form of cytosine (C) to thymine (T) ratios to decipher the ancient methylomes of
192 Neanderthals and Denisovans. Subsequently, they compared the methylomes of
193 Neanderthals, Denisovans and modern humans and inferred the species in which the
194 methylation variation likely took place; this information was used to classify the
195 DMRs as Neanderthal-specific, Denisovan-specific and human-specific. These DMRs
196 represent species-specific methylation (Gokhman et al., 2014).

197

198 *2.4. Neanderthal selective sweep (NSS) data*

199 We obtained NSS marker data from Srinivasan et al. (2015). Negative scores for NSS
200 markers indicate positive selection in humans. Markers with such scores were used in
201 the downstream analyses.

202

203 *2.5. SNP assignment with LDsnpr*

204 The previously published R-based software package LDsnpr (Christoforou et al.,
205 2012) was utilized for assigning SNPs to the respective DMRs using LD (linkage
206 disequilibrium)-based binning at $r^2 \geq 0.8$ in R (R Core Team, 2017). LD-based binning
207 makes it possible to determine whether SNPs from a specific GWAS are in LD with
208 the DMR of interest. Using LD allows the capture of a greater number of relevant
209 SNPs in comparison to an approach where only physically overlapping SNPs are
210 considered. The LD file utilized was in HDF5 format and was constructed from the
211 European reference population of 1KGP and can be publicly downloaded at:
212 <http://services.cbu.uib.no/software/ldsnpr/Download>.

213

214 *2.6. Enrichment analyses based on stratified quantile-quantile (QQ) plots*

215 QQ plots are an essential method used in GWASs to depict the presence of true
216 signals. They help to visually observe the spread of data and deviations from the null
217 distribution. Under the null hypothesis, no difference is expected between the
218 observed and expected distributions of data. As such, a line of no difference or null
219 line is obtained that is equidistant from both X and Y axes. However, if the null
220 hypothesis were to be false, there would be a deviation of the observed data
221 distribution from the expected data distribution. As described in depth by Schork et al.
222 (2013), a leftward deflection of the observed distribution from the null line represents
223 enrichment – the greater the leftward deflection, the stronger the enrichment of true

224 signals. This method has been used recently not only to show how specific genomic
225 annotation affects the distribution of disease SNPs with true signals (Schork et al.,
226 2013), but also to demonstrate that regions of recent evolution are enriched for
227 schizophrenia markers (Banerjee et al., 2017; Srinivasan et al., 2015). We took the
228 SNPs that are in LD with the DMR regions and plotted their p -value distributions
229 from various GWASs. The observed p -value distributions were then determined to be
230 enriched or not using conditional Q-Q plots as described by Schork et al. (2013).
231 Genomic inflation was corrected by λ_{GC} .

232

233 *2.7. INRICH-based enrichment analysis*

234 The stratified QQ plots provide a visual depiction of data distributions and enrichment
235 of true signals within a stratum of data, but they do not quantify this enrichment.
236 Therefore, we used the INterval EnRICHment (INRICH) analysis tool to statistically
237 quantify the enrichment observed. This pipeline performs permutation and
238 bootstrapping procedures to determine with statistical confidence whether LD-
239 implicated genomic intervals are enriched in specific gene sets (Lee et al., 2012). The
240 INRICH analysis takes into account several potential biases that can otherwise lead to
241 false positives, such as variable gene size, SNP density within genes, LD between and
242 within genes, and overlapping genes in the gene sets. We used the same procedure
243 reported previously (Banerjee et al., 2017; Xu et al., 2015) with SNPs in the extended
244 MHC region and SNPs with MAF <0.05 excluded from the analysis. Additional
245 details can be found in the Supplementary Information.

246

247 **3. Results**

248

249 *3.1. Co-localisation of human hypo-methylated regions and genetic variants*

250 *associated with schizophrenia in the MHC.*

251 We ascertained whether there is any enrichment of human hypo- and hyper-
252 methylated regions in schizophrenia-associated SNPs. Using previously published
253 methodology (Christoforou et al., 2012), we mapped schizophrenia markers to human
254 hypo-methylated regions (hypo-DMRs) and hyper-methylated regions (hyper-DMRs).
255 Out of a total of ~9.4 million SCZ markers obtained from the GWAS, 10,165 markers
256 tagged hypo-DMRs and 4,503 tagged hyper-DMRs.

257

258 Figure 1A shows the conditional QQ plots for schizophrenia markers (all markers, the
259 hypo-DMR set and the hyper-DMR set) including those in the MHC region. For
260 hypo-DMR markers (Supplementary Dataset 1), we observed a significant enrichment
261 as depicted by the leftward deviation. No enrichment was observed for hyper-DMR
262 markers. Since the MHC region is a region of extended linkage disequilibrium, which
263 can bias the enrichment estimates, and since it is the main region of association with
264 schizophrenia, we also tested the enrichment with the MHC region removed (Figure
265 1B). Under these conditions there is a trend for enrichment of hypo-DMR markers at
266 higher p -value thresholds, but this enrichment is substantially less than when the
267 MHC is included (Figure 1A).

268

269 *3.2. Enrichment of markers is not seen for other human traits*

270 Next, we tested if the human hypo- and hyper-methylated regions are enriched for
271 other human traits and phenotypes. We tested a total of thirteen different phenotypes,
272 full details of which can be found in section 2.1. Each GWAS had been performed
273 with a different number of genotyped SNPs, and this difference could potentially bias

274 our results. To circumvent this, we created a list of ~2.4 million common SNPs that
275 were genotyped across all the phenotypes investigated in the present study. Only
276 SNPs on this list were used for enrichment analysis.

277

278 As can be seen in Fig. 2, no enrichment was observed in any of the traits, with the
279 possible exception of height at higher p -value threshold markers. The common list of
280 markers did not contain the MHC region and as such no enrichment is observed for
281 schizophrenia either.

282

283 *3.3. Evidence of enrichment for hypo-methylated regions with SNPs at high p -values*

284 The enrichment plots allowed us to visually ascertain enrichment in the datasets.

285 However, they did not give any indication of the statistical robustness of the

286 enrichment. To ascertain if the human hypo- and hyper-methylated regions are

287 statistically enriched for schizophrenia and height markers, we implemented the

288 INRICH pipeline, which performs 10,000 permutations and 5,000 bootstrapping

289 calculations, to determine with statistical confidence the enrichment observed (Lee et

290 al., 2012).

291

292 The INRICH analysis confirmed a significant ($p < 0.05$) enrichment of association for

293 human hypo-DMRs, but not hyper-DMRs, with schizophrenia at SNPs of higher p -

294 value thresholds ($p < 10e-3$ to $p < 10e-4$) (Fig. 3). This enrichment was at the gene level,

295 and complemented the enrichment observed at the SNP level for higher p -value

296 thresholds (Fig. 1B). Importantly, this enrichment persisted upon testing a pruned

297 schizophrenia dataset (Supplementary Fig. 1). The enrichment was however not

298 significant at the genome-wide threshold ($p < 5 \times 10e-8$) and was much weaker than that

299 observed for non-primate DMRs (Fig. 3). We also observed a similar trend for height
300 where there was enrichment at SNPs of higher but not lower p -value thresholds. This
301 enrichment was similarly less pronounced than for non-primate DMRs
302 (Supplementary Fig. 2).

303

304

305 **4. Discussion**

306

307 In our study, we investigated if regions of the human genome whose methylation has
308 evolved since the divergence of modern humans from great apes are enriched for
309 markers of schizophrenia. We found evidence that there is enrichment for hypo-
310 methylated DMRs driven by the MHC locus, a known risk region that harbours the
311 most significant schizophrenia GWAS markers (Ripke et al., 2014). When the MHC
312 region was excluded from the analysis, there remained a trend towards enrichment of
313 hypo-DMRs driven by SNPs of higher p -value thresholds. This finding was
314 complemented by the INRICH analyses that indicated significant enrichment among
315 SNPs of higher p -value thresholds. When analysing a global SNP list common to
316 GWAS of several traits, we failed to find evidence of enrichment of any trait with the
317 possible exception of height at higher SNP p -value thresholds. We tested this further
318 with the INRICH pipeline, which revealed gene-level enrichment of LD intervals for
319 height markers below the genome-wide threshold ($p < 5 \times 10^{-8}$). Compared to our
320 previous study, in which we demonstrated enrichment of association with
321 schizophrenia for non-primate DMRs that were derived by comparing human,
322 Neanderthal and Denisovan methylomes (Banerjee et al., 2017), the primate DMRs
323 tested here show far less enrichment. The primate and non-primate DMRs have very

324 little overlap, which suggests that the methylation changes that took place since the
325 divergence of modern humans from Neanderthals and Denisovans occurred in
326 different regions of the genome compared to those that took place since divergence
327 from great apes.
328
329 The central role of the MHC region in the enrichment of human hypo-methylated
330 regions poses interesting questions. The MHC region is known for its complex LD
331 architecture, which renders the interpretation of genetic signals very challenging.
332 Other groups have previously reported that the MHC region is one of the fastest
333 evolving regions of the human genome (Meyer et al., 2017) and have implicated it in
334 mate preference (Bernatchez and Landry, 2003; Kromer et al., 2016; Potts and
335 Wakeland, 1990; Roberts et al., 2008; Winternitz et al., 2017), odour perception
336 (Roberts et al., 2008; Santos et al., 2005) and immune response (Benacerraf, 1981;
337 Horton et al., 2004). Recently it was shown that a large proportion of the association
338 of the region with schizophrenia can be explained by complement C4 haplotypes that
339 include C4 copy number variation (Sekar et al., 2016). Nevertheless, there remains a
340 part of the association in this region that is unexplained (Gejman et al., 2011) and will
341 need further investigation. It is interesting to consider the possibility that the MHC
342 region and the immune system in general play a central role in evolution at the
343 epigenomic as well as at the genomic level (Meyer et al., 2017; Potts and Wakeland,
344 1990; Sommer, 2005; Traherne, 2008). The mechanisms by which hypo-methylation
345 could influence the aforementioned processes are open to speculation since the MHC
346 region has more than 200 genes in close physical proximity and LD with one another
347 (Beck et al., 1999). This makes it hard to interpret the exact biological consequences
348 of our findings.

349

350 Interestingly, the gene-level analysis via INRICH seems to suggest enrichment of
351 SNPs of higher p -value thresholds in primate DMRs for both schizophrenia and
352 height. This enrichment is far lower than what we found for non-primate DMRs for
353 both schizophrenia and height (Banerjee et al., 2017) and which persisted for
354 schizophrenia even with pruned datasets.

355

356 The very small overlap between primate and non-primate DMRs might suggest that
357 the divergence from Neanderthals and Denisovans brought about more significant
358 methylation changes in regions implicated in the aetiology of schizophrenia and
359 height than the divergence from great apes. In other words, our results might suggest
360 that the evolutionary factors that regulate methylation variation acted on different
361 segments of the genome at different time points. So while the methylation variation
362 since the divergence from Neanderthals and Denisovans may mark a genome-wide
363 increase of schizophrenia susceptibility (Banerjee et al., 2017), the methylation
364 variation from the time period between 13 and 6 MYA appears not to have
365 significantly increased the risk for schizophrenia (except possibly for some markers in
366 the MHC region),

367

368 Our results are also in line with the findings of Srinivasan et al. (2017), who failed to
369 find evidence of enrichment of schizophrenia using genomic markers of evolution
370 dating back to 200 MYA. The same authors also reported enrichment of association
371 for regions of more recent evolution in modern humans (Srinivasan et al., 2015).
372 Interestingly, one of the evolutionary proxies used by Srinivasan and colleagues
373 (2017), namely HARs, also showed enrichment for height, similar to our recent study

374 (Banerjee et al., 2017). This suggests that regions controlling both genomic and
375 epigenomic variation in height may also be driven by recent evolution. Finally, our
376 results agree well with the observation by Srinivasan et al. (2017) of some
377 involvement of the MHC in an early evolutionary context.

378

379 Although our results are in line with several findings in the field, the current methods
380 have some limitations. Highly polygenic traits such as schizophrenia have a large
381 number of genetic loci contributing to the aetiology of a disease (Bulik-Sullivan et al.,
382 2015; Schork et al., 2016). The ability to detect these large numbers of genetic loci is
383 dependent on the sample size and adequate statistical power (Schork et al., 2016).
384 Consequently, the polygenic enrichment methods may be limited by the statistical
385 power of the respective GWAS and trait polygenicity. Furthermore, in the INRICH
386 analysis that uses LD-clumping of SNPs at $p < 10e-3$ to $p < 10e-8$, higher p -value
387 thresholds (e.g. $p < 10e-3$) still include SNPs of lower p -values, even though they
388 become progressively smaller minorities. Thus, although higher p -values increase the
389 number of LD-clumps tested, we do not expect this to increase the Type I error rate
390 (Lee et al., 2012).

391

392 In conclusion, our results suggest that methylation markers tracing an evolutionary
393 period dating back to 13 MYA (primate DMRs) are not enriched for schizophrenia
394 markers, unlike methylation markers from a recent timeframe (non-primate DMRs)
395 (Banerjee et al., 2017). Taken in consideration with previous studies of genomic
396 markers of evolution dating back 200 MYA (Srinivasan et al., 2017), our results
397 support the hypothesis that the origins of schizophrenia lie in more recent

398 evolutionary events, possibly after the divergence of modern-day humans from

399 Neanderthals and Denisovans.

400

401

402 **Appendix A. Supplementary data**

403 Supplementary Information: Additional Methods, Figures and Tables

404 Supplementary Dataset 1: Annotation of human hypo-methylated regions with

405 markers of schizophrenia

406

407 **References**

408

409 Ayuso-Mateos, J.L., 2002. Global Burden of schizophrenia in the year 2000-Version
410 1 Estimates. World Health Organization.

411

412 Banerjee, N., Polushina, T., Bettella, F., Giddaluru, S., Steen, V.M., Andreassen,
413 O.A., Le Hellard, S., 2017. Human-specific methylated regions are enriched in
414 schizophrenia. bioRxiv 113175.

415

416 Bassett, A.S., Bury, A., Hodgkinson, K.A., Honer, W.G., 1996. Reproductive fitness
417 in familial schizophrenia. *Schizophr. Res.* 21, 151–60.

418

419 Beck, S., Geraghty, D., Inoko, H., Rowen, L., 1999. Complete sequence and gene
420 map of a human major histocompatibility complex. *Nature* 401, 921–923.

421

422 Benacerraf, B., 1981. Role of MHC gene products in immune regulation. *Science*
423 212, 1229–1238.

424

425 Bernatchez, L., Landry, C., 2003. MHC studies in nonmodel vertebrates: what have
426 we learned about natural selection in 15 years? *J. Evol. Biol.* 16, 363–77.

427

428 Bernstein, B.E., Meissner, A., Lander, E.S., 2007. The mammalian epigenome. *Cell*
429 128, 669 – 681.

430

431 Bird, C.P., Stranger, B.E., Liu, M., Thomas, D.J., Ingle, C.E., Beazley, C., Miller, W.,
432 Hurles, M.E., Dermitzakis, E.T., 2007. Fast-evolving noncoding sequences in the
433 human genome. *Genome Biol.* 8, R118.

434

435 Brown, S., 1997. Excess mortality of schizophrenia. A meta-analysis. *Br. J.*
436 *Psychiatry* 171, 502–508.

437

438 Brüne, M., 2004. Schizophrenia—an evolutionary enigma? *Neurosci. Biobehav. Rev.*
439 28, 41–53.

440

441 Bulik-Sullivan, B.K., Loh, P.-R., Finucane, H.K., Ripke, S., Yang, J., Patterson, N.,
442 Daly, M.J., Price, A.L., Neale, B.M., Schizophrenia Working Group of the
443 Psychiatric Genomics Consortium, 2015. LD Score regression distinguishes
444 confounding from polygenicity in genome-wide association studies. *Nature Genet.*
445 47, 291.

446

447 Burbano, H.A., Hodges, E., Green, R.E., Briggs, A.W., Krause, J., Meyer, M., Good,
448 J.M., Maricic, T., Johnson, P.L.F., Xuan, Z., Rooks, M., Bhattacharjee, A.,
449 Brizuela, L., Albert, F.W., de la Rasilla, M., Fortea, J., Rosas, A., Lachmann, M.,
450 Hannon, G.J., Pääbo, S., 2010. Targeted investigation of the Neandertal genome by
451 array-based sequence capture. *Science* 328, 723–5.

452

- 453 Bush, E.C., Lahn, B.T., 2008. A genome-wide screen for noncoding elements
454 important in primate evolution. *BMC Evol. Biol.* 8, 17.
455
- 456 Cardno, A.G., Marshall, E.J., Coid, B., Macdonald, A.M., Ribchester, T.R., Davies,
457 N.J., Venturi, P., Jones, L.A., Lewis, S.W., Sham, P.C., et al., 1999. Heritability
458 estimates for psychotic disorders: the Maudsley twin psychosis series. *Arch. Gen.*
459 *Psychiatry* 56, 162–168.
460
- 461 Christoforou, A., Dondrup, M., Mattingsdal, M., Mattheisen, M., Giddaluru, S.,
462 Nøthen, M.M., Rietschel, M., Cichon, S., Djurovic, S., Andreassen, O.A., et al.,
463 2012. Linkage-disequilibrium-based binning affects the interpretation of GWASs.
464 *Am. J. Hum. Genet.* 90, 727–733.
465
- 466 Crespi, B., Summers, K., Dorus, S., 2007. Adaptive evolution of genes underlying
467 schizophrenia. *Proc. Roy. Soc. Lond. [Biol]* 274, 2801–2810.
468
- 469 Crow, T.J., 1995. A Darwinian approach to the origins of psychosis. *Br. J. Psychiatry*
470 167, 12–25.
471
- 472 Crow, T.J., 1997. Is schizophrenia the price that Homo sapiens pays for language?
473 *Schizophr. Res.* 28, 127–41.
474
- 475 Crow, T.J., 2000. Schizophrenia as the price that Homo sapiens pays for language: a
476 resolution of the central paradox in the origin of the species. *Brain Research*
477 *Reviews* 31, 118–129.
478
- 479 Crow, T.J., 2008. The “big bang” theory of the origin of psychosis and the faculty of
480 language. *Schizophr. Res.* 102, 31–52.
481
- 482 Demontis, D., Walters, R.K., Martin, J., Mattheisen, M., Als, T.D., Agerbo, E.,
483 Belliveau, R., Bybjerg-Grauholm, J., Bækved-Hansen, M., Cerrato, F., et al., 2017.
484 Discovery of the first genome-wide significant risk loci for ADHD. *bioRxiv*
485 145581.
486
- 487 Durbin, R., Abecasis, G., Bentley, D., Chakravarti, A., Clark, A., Donnelly, P.,
488 Eichler, E., Flicek, P., Gabriel, S., Gibbs, R., et al., 2012. An integrated map of
489 genetic variation from 1,092 human genomes. *Nature* 497, 56–65.
490
- 491 Ehret, G.B., Munroe, P.B., Rice, K.M., Bochud, M., Johnson, A.D., Chasman, D.I.,
492 Smith, A.V., Tobin, M.D., Verwoert, G.C., Hwang, S.-J., et al., 2011. Genetic
493 variants in novel pathways influence blood pressure and cardiovascular disease
494 risk. *Nature* 478, 103.
495
- 496 Gejman, P.V., Sanders, A.R., Kendler, K.S., 2011. Genetics of schizophrenia: new
497 findings and challenges. *Annu. Rev. Genomics Hum. Genet.* 12, 121–44.
498
- 499 Gittelman, R.M., Hun, E., Ay, F., Madeoy, J., Pennacchio, L., Noble, W.S., Hawkins,
500 R.D., Akey, J.M., 2015. Comprehensive identification and analysis of human
501 accelerated regulatory DNA. *Genome Res.* 25, 1245–1255.
502

- 503 Glazko, G.V., Nei, M., 2003. Estimation of divergence times for major lineages of
504 primate species. *Mol. Biol. Evol.* 20, 424–34.
505
- 506 Gokhman, D., Lavi, E., Prüfer, K., Fraga, M.F., Riancho, J.A., Kelso, J., Pääbo, S.,
507 Meshorer, E., Carmel, L., 2014. Reconstructing the DNA methylation maps of the
508 Neandertal and the Denisovan. *Science* 344, 523–527.
509
- 510 Green, R.E., Krause, J., Briggs, A.W., Maricic, T., Stenzel, U., Kircher, M., Patterson,
511 N., Li, H., Zhai, W., Fritz, M.H.-Y., et al., 2010. A draft sequence of the
512 Neandertal genome. *Science* 328, 710–722.
513
- 514 Hasegawa, M., Kishino, H., Yano, T., 1985. Dating of the human-ape splitting by a
515 molecular clock of mitochondrial DNA. *J. Mol. Evol.* 22, 160–74.
516
- 517 Hernando-Herraez, I., Heyn, H., Fernandez-Callejo, M., Vidal, E., Fernandez-Bellon,
518 H., Prado-Martinez, J., Sharp, A.J., Esteller, M., Marques-Bonet, T., 2015. The
519 interplay between DNA methylation and sequence divergence in recent human
520 evolution. *Nucleic Acids Res.* 43, 8204–8214.
521
- 522 Hernando-Herraez, I., Prado-Martinez, J., Garg, P., Fernandez-Callejo, M., Heyn, H.,
523 Hvilsom, C., Navarro, A., Esteller, M., Sharp, A.J., Marques-Bonet, T., 2013.
524 Dynamics of DNA methylation in recent human and great ape evolution. *PLoS*
525 *Genet* 9, e1003763.
526
- 527 Horton, R., Wilming, L., Rand, V., Lovering, R.C., Bruford, E.A., Khodiyar, V.K.,
528 Lush, M.J., Povey, S., Talbot Jr, C.C., Wright, M.W., et al., 2004. Gene map of the
529 extended human MHC. *Nat. Rev. Genet.* 5, 889-899.
530
- 531 Jeste, D.V., Del Carmen, R., Lohr, J.B., Wyatt, R.J., 1985. Did schizophrenia exist
532 before the eighteenth century? *Compr. Psychiatry* 26, 493–503.
533
- 534 Karolchik, D., Barber, G.P., Casper, J., Clawson, H., Cline, M.S., Diekhans, M.,
535 Dreszer, T.R., Fujita, P.A., Guruvadoo, L., Haeussler, M., Harte, R.A., Heitner, S.,
536 Hinrichs, A.S., Learned, K., Lee, B.T., Li, C.H., Raney, B.J., Rhead, B.,
537 Rosenbloom, K.R., Sloan, C.A., Speir, M.L., Zweig, A.S., Haussler, D., Kuhn,
538 R.M., Kent, W.J., 2014. The UCSC Genome Browser database: 2014 update.
539 *Nucleic Acids Res.* 42, D764–70.
540
- 541 Kromer, J., Hummel, T., Pietrowski, D., Giani, A., Sauter, J., Ehninger, G., Schmidt,
542 A., Croy, I., 2016. Influence of HLA on human partnership and sexual satisfaction.
543 *Scientific Reports* 6, 32550.
544
- 545 Kundaje, A., Meuleman, W., Ernst, J., Bilenky, M., Yen, A., Heravi-Moussavi, A.,
546 Kheradpour, P., Zhang, Z., Wang, J., Ziller, M.J., et al., 2015. Integrative analysis
547 of 111 reference human epigenomes. *Nature* 518, 317–330.
548
- 549 Kyaga, S., Lichtenstein, P., Boman, M., Hultman, C., Långström, N., Landén, M.,
550 2011. Creativity and mental disorder: family study of 300 000 people with severe
551 mental disorder. *Brit. J. Psych.* 199, 373–379.
552

- 553 Lander, E.S., Linton, L.M., Birren, B., Nusbaum, C., Zody, M.C., Baldwin, J., Devon,
554 K., Dewar, K., Doyle, M., FitzHugh, W., et al., 2001. Initial sequencing and
555 analysis of the human genome. *Nature* 409, 860-921.
556
- 557 Langergraber, K.E., Prüfer, K., Rowney, C., Boesch, C., Crockford, C., Fawcett, K.,
558 Inoue, E., Inoue-Muruyama, M., Mitani, J.C., Muller, M.N., Robbins, M.M.,
559 Schubert, G., Stoinski, T.S., Viola, B., Watts, D., Wittig, R.M., Wrangham, R.W.,
560 Zuberbühler, K., Pääbo, S., Vigilant, L., 2012. Generation times in wild
561 chimpanzees and gorillas suggest earlier divergence times in great ape and human
562 evolution. *Proc. Natl. Acad. Sci. U.S.A.* 109, 15716–15721.
563
- 564 Larson, C.A., Nyman, G.E., 1973. Differential fertility in schizophrenia. *Acta*
565 *Psychiatr Scand* 49, 272–80.
566
- 567 Lee, P.H., O’Dushlaine, C., Thomas, B., Purcell, S.M., 2012. INRICH: interval-based
568 enrichment analysis for genome-wide association studies. *Bioinformatics* 28,
569 1797–9.
570
- 571 Lichtenstein, P., Yip, B.H., Björk, C., Pawitan, Y., Cannon, T.D., Sullivan, P.F.,
572 Hultman, C.M., 2009. Common genetic determinants of schizophrenia and bipolar
573 disorder in Swedish families: a population-based study. *Lancet* 373, 234–239.
574
- 575 Lindblad-Toh, K., Garber, M., Zuk, O., Lin, M.F., Parker, B.J., Washietl, S.,
576 Kheradpour, P., Ernst, J., Jordan, G., Mauceli, E., Ward, L.D., Lowe, C.B.,
577 Holloway, A.K., Clamp, M., Gnerre, S., Alkhalidi, J., Beal, K., Chang, J., Clawson,
578 H., Cuff, J., Di Palma, F., Fitzgerald, S., Flicek, P., Guttman, M., Hubisz, M.J.,
579 Jaffe, D.B., Jungreis, I., Kent, W.J., Kostka, D., Lara, M., Martins, A.L.,
580 Massingham, T., Moltke, I., Raney, B.J., Rasmussen, M.D., Robinson, J., Stark, A.,
581 Vilella, A.J., Wen, J., Xie, X., Zody, M.C., Baldwin, J., Bloom, T., Whye Chin, C.,
582 Heiman, D., Nicol, R., Nusbaum, C., Young, S., Wilkinson, J., Worley, K.C.,
583 Kovar, C.L., Muzny, D.M., Gibbs, R. a., Cree, A., Dihm, H.H., Fowler, G.,
584 Jhangiani, S., Joshi, V., Lee, S., Lewis, L.R., Nazareth, L.V., Okwuonu, G.,
585 Santibanez, J., Warren, W.C., Mardis, E.R., Weinstock, G.M., Wilson, R.K.,
586 Delehaunty, K., Dooling, D., Fronik, C., Fulton, L., Fulton, B., Graves, T., Minx,
587 P., Sodergren, E., Birney, E., Margulies, E.H., Herrero, J., Green, E.D., Haussler,
588 D., Siepel, A., Goldman, N., Pollard, K.S., Pedersen, J.S., Lander, E.S., Kellis, M.,
589 2011. A high-resolution map of human evolutionary constraint using 29 mammals.
590 *Nature* 478, 476–482.
591
- 592 Locke, A.E., Kahali, B., Berndt, S.I., Justice, A.E., Pers, T.H., Day, F.R., Powell, C.,
593 Vedantam, S., Buchkovich, M.L., Yang, J., et al., 2015. Genetic studies of body
594 mass index yield new insights for obesity biology. *Nature* 518, 197–206.
595
- 596 Markow, T.A., 2012. Developmental instability: its origins and evolutionary
597 implications: proceedings of the International Conference on Developmental
598 Instability: Its Origins and Evolutionary Implications, Tempe, Arizona, 14-15 June
599 1993. Springer Science and Business Media.
600

- 601 Mendizabal, I., Keller, T., Zeng, J., Soojin, V.Y., 2014. Epigenetics and evolution.
602 *Integr. Comp. Biol.* 54, 31–42.
603
- 604 Messias, E.L., Chen, C.-Y., Eaton, W.W., 2007. Epidemiology of schizophrenia:
605 review of findings and myths. *Psychiatr. Clin. North Am.* 30, 323–38.
606
- 607 Meyer, D., Aguiar, V.R., Bitarello, B.D., Brandt, D.Y., Nunes, K., 2017. A genomic
608 perspective on HLA evolution. *Immunogenetics* 70, 1–23.
609
- 610 Molaro, A., Hodges, E., Fang, F., Song, Q., McCombie, W.R., Hannon, G.J., Smith,
611 A.D., 2011. Sperm methylation profiles reveal features of epigenetic inheritance
612 and evolution in primates. *Cell* 146, 1029–1041.
613
- 614 Nichols, C., 2009. Is there an evolutionary advantage of schizophrenia? *Pers. Individ.*
615 *Diff.* 46, 832–838.
616
- 617 Paaby, A.B., Rockman, M.V., 2014. Cryptic genetic variation: evolution’s hidden
618 substrate. *Nat. Rev. Genet.* 15, 247–258
619
- 620 Pollard, K.S., Salama, S.R., King, B., Kern, A.D., Dreszer, T., Katzman, S., Siepel,
621 A., Pedersen, J.S., Bejerano, G., Baertsch, R., et al., 2006. Forces shaping the
622 fastest evolving regions in the human genome. *PLoS Genet* 2, e168.
623
- 624 Potts, W.K., Wakeland, E.K., 1990. Evolution of diversity at the major
625 histocompatibility complex. *Trends Ecol. Evol. (Amst.)* 5, 181–7.
626
- 627 Power, R.A., Kyaga, S., Uher, R., MacCabe, J.H., Långström, N., Landen, M.,
628 McGuffin, P., Lewis, C.M., Lichtenstein, P., Svensson, A.C., 2013. Fecundity of
629 patients with schizophrenia, autism, bipolar disorder, depression, anorexia nervosa,
630 or substance abuse vs their unaffected siblings. *JAMA Psychiatry* 70, 22–30.
631
- 632 Rannala, B., Yang, Z., 2003. Bayes estimation of species divergence times and
633 ancestral population sizes using DNA sequences from multiple loci. *Genetics* 164,
634 1645–1656.
635
- 636 R Core Team, 2017. *R: A Language and Environment for Statistical Computing.*
637 Vienna, Austria.
638
- 639 Ripke, S., Neale, B.M., Corvin, A., Walters, J.T., Farh, K.-H., Holmans, P.A., Lee, P.,
640 Bulik-Sullivan, B., Collier, D.A., Huang, H., et al., 2014. Biological insights from
641 108 schizophrenia-associated genetic loci. *Nature* 511, 421–427.
642
- 643 Rivera, C.M., Ren, B., 2013. Mapping human epigenomes. *Cell* 155, 39–55.
644
- 645 Roberts, S.C., Gosling, L.M., Carter, V., Petrie, M., 2008. MHC-correlated odour
646 preferences in humans and the use of oral contraceptives. *Proc. Biol. Sci.* 275,
647 2715–2722.
648
- 649 Santos, P.S.C., Schinemann, J.A., Gabardo, J., Bicalho, M. da G., 2005. New
650 evidence that the MHC influences odor perception in humans: a study with 58

- 651 Southern Brazilian students. *Horm. Behav.* 47, 384–388.
- 652
- 653 Schork, A.J., Thompson, W.K., Pham, P., Torkamani, A., Roddey, J.C., Sullivan,
654 P.F., Kelsoe, J.R., O'Donovan, M.C., Furberg, H., Schork, N.J., et al., 2013. All
655 SNPs are not created equal: genome-wide association studies reveal a consistent
656 pattern of enrichment among functionally annotated SNPs. *PLoS Genet* 9,
657 e1003449.
- 658
- 659 Schork, A.J., Wang, Y., Thompson, W.K., Dale, A.M., Andreassen, O.A., 2016. New
660 statistical approaches exploit the polygenic architecture of schizophrenia—
661 implications for the underlying neurobiology. *Curr. Opin. Neurobiol.* 36, 89–98.
- 662
- 663 Sekar, A., Bialas, A.R., de Rivera, H., Davis, A., Hammond, T.R., Kamitaki, N.,
664 Tooley, K., Presumey, J., Baum, M., Van Doren, V., et al., 2016. Schizophrenia
665 risk from complex variation of complement component 4. *Nature* 530, 177–183.
- 666
- 667 Sklar, P., Ripke, S., Scott, L.J., Andreassen, O.A., Cichon, S., Craddock, N.,
668 Edenberg, H.J., Nurnberger, J.I., Rietschel, M., Blackwood, D., et al., 2011. Large-
669 scale genome-wide association analysis of bipolar disorder identifies a new
670 susceptibility locus near ODZ4. *Nature Genet.* 43, 977–983.
- 671
- 672 Skre, I., Onstad, S., Torgersen, S., Lygren, S., Kringlen, E., 1993. A twin study of
673 DSM-III-R anxiety disorders. *Acta Psychiatr. Scand.* 88, 85–92.
- 674
- 675 Sniekers, S., Stringer, S., Watanabe, K., Jansen, P.R., Coleman, J.R., Krapohl, E.,
676 Taskesen, E., Hammerschlag, A.R., Okbay, A., Zabaneh, D., et al., 2017. Genome-
677 wide association meta-analysis of 78,308 individuals identifies new loci and genes
678 influencing human intelligence. *Nature Genet.* 49, 1107–1112.
- 679
- 680 Sommer, S., 2005. The importance of immune gene variability (MHC) in
681 evolutionary ecology and conservation. *Front. Zool.* 2, 16.
- 682
- 683 Srinivasan, S., Bettella, F., Hassani, S., Wang, Y., Witoelar, A., Schork, A.J.,
684 Thompson, W.K., Collier, D.A., Desikan, R.S., Melle, I., et al., 2017. Probing the
685 association between early evolutionary markers and schizophrenia. *PLoS One* 12,
686 e0169227.
- 687
- 688 Srinivasan, S., Bettella, F., Mattingsdal, M., Wang, Y., Witoelar, A., Schork, A.J.,
689 Thompson, W.K., Zuber, V., Winsvold, B.S., Zwart, J.-A., et al., 2015. Genetic
690 markers of human evolution are enriched in schizophrenia. *Biol. Psychiatry* 80,
691 284–292.
- 692
- 693 Stahl, E.A., Raychaudhuri, S., Remmers, E.F., Xie, G., Eyre, S., Thomson, B.P., Li,
694 Y., Kurreeman, F.A., Zhernakova, A., Hinks, A., et al., 2010. Genome-wide
695 association study meta-analysis identifies seven new rheumatoid arthritis risk loci.
696 *Nature Genet.* 42, 508–514.
- 697
- 698 Sullivan, P.F., Kendler, K.S., Neale, M.C., 2003. Schizophrenia as a complex trait:
699 evidence from a meta-analysis of twin studies. *Arch. Gen. Psychiatry* 60, 1187–

700 1192.

701

702 Teslovich, T.M., Musunuru, K., Smith, A.V., Edmondson, A.C., Stylianou, I.M.,
703 Koseki, M., Pirruccello, J.P., Ripatti, S., Chasman, D.I., Willer, C.J., Johansen,
704 C.T., Fouchier, S.W., Isaacs, A., Peloso, G.M., Barbalic, M., Ricketts, S.L., Bis,
705 J.C., Aulchenko, Y.S., Thorleifsson, G., Feitosa, M.F., Chambers, J., Orho-
706 Melander, M., Melander, O., Johnson, T., Li, X., Guo, X., Li, M., Shin Cho, Y., Jin
707 Go, M., Jin Kim, Y., Lee, J.-Y., Park, T., Kim, K., Sim, X., Twee-Hee Ong, R.,
708 Croteau-Chonka, D.C., Lange, L.A., Smith, J.D., Song, K., Hua Zhao, J., Yuan, X.,
709 Luan, J., Lamina, C., Ziegler, A., Zhang, W., Zee, R.Y.L., Wright, A.F., Witteman,
710 J.C.M., Wilson, J.F., Willemsen, G., Wichmann, H.-E., Whitfield, J.B.,
711 Waterworth, D.M., Wareham, N.J., Waeber, G., Vollenweider, P., Voight, B.F.,
712 Vitart, V., Uitterlinden, A.G., Uda, M., Tuomilehto, J., Thompson, J.R., Tanaka,
713 T., Surakka, I., Stringham, H.M., Spector, T.D., Soranzo, N., Smit, J.H., Sinisalo,
714 J., Silander, K., Sijbrands, E.J.G., Scuteri, A., Scott, J., Schlessinger, D., Sanna, S.,
715 Salomaa, V., Saharinen, J., Sabatti, C., Ruukonen, A., Rudan, I., Rose, L.M.,
716 Roberts, R., Rieder, M., Psaty, B.M., Pramstaller, P.P., Pichler, I., Perola, M.,
717 Penninx, B.W.J.H., Pedersen, N.L., Pattaro, C., Parker, A.N., Pare, G., Oostra,
718 B.A., O'Donnell, C.J., Nieminen, M.S., Nickerson, D.A., Montgomery, G.W.,
719 Meitinger, T., McPherson, R., McCarthy, M.I., McArdle, W., Masson, D., Martin,
720 N.G., Marroni, F., Mangino, M., Magnusson, P.K.E., Lucas, G., Luben, R., Loos,
721 R.J.F., Lokki, M.-L., Lettre, G., Langenberg, C., Launer, L.J., Lakatta, E.G.,
722 Laaksonen, R., Kyvik, K.O., Kronenberg, F., König, I.R., Khaw, K.-T., Kaprio, J.,
723 Kaplan, L.M., Johansson, A., Jarvelin, M.-R., Janssens, A.C.J.W., Ingelsson, E.,
724 Igl, W., Kees Hovingh, G., Hottenga, J.-J., Hofman, A., Hicks, A.A.,
725 Hengstenberg, C., Heid, I.M., Hayward, C., Havulinna, A.S., Hastie, N.D., Harris,
726 T.B., Haritunians, T., Hall, A.S., Gyllensten, U., Guiducci, C., Groop, L.C.,
727 Gonzalez, E., Gieger, C., Freimer, N.B., Ferrucci, L., Erdmann, J., Elliott, P.,
728 Ejebe, K.G., Döring, A., Dominiczak, A.F., Demissie, S., Deloukas, P., de Geus,
729 E.J.C., de Faire, U., Crawford, G., Collins, F.S., Chen, Y.I., Caulfield, M.J.,
730 Campbell, H., Burt, N.P., Bonnycastle, L.L., Boomsma, D.I., Boehholdt, S.M.,
731 Bergman, R.N., Barroso, I., Bandinelli, S., Ballantyne, C.M., Assimes, T.L.,
732 Quertermous, T., Altshuler, D., Seielstad, M., Wong, T.Y., Tai, E.-S., Feranil,
733 A.B., Kuzawa, C.W., Adair, L.S., Taylor, H.A., Borecki, I.B., Gabriel, S.B.,
734 Wilson, J.G., Holm, H., Thorsteinsdottir, U., Gudnason, V., Krauss, R.M., Mohlke,
735 K.L., Ordovas, J.M., Munroe, P.B., Kooner, J.S., Tall, A.R., Hegele, R.A.,
736 Kastelein, J.J.P., Schadt, E.E., Rotter, J.I., Boerwinkle, E., Strachan, D.P., Mooser,
737 V., Stefansson, K., Reilly, M.P., Samani, N.J., Schunkert, H., Cupples, L.A.,
738 Sandhu, M.S., Ridker, P.M., Rader, D.J., van Duijn, C.M., Peltonen, L., Abecasis,
739 G.R., Boehnke, M., Kathiresan, S., 2010. Biological, clinical and population
740 relevance of 95 loci for blood lipids. *Nature* 466, 707–713.

741

742 Traherne, J., 2008. Human MHC architecture and evolution: implications for disease
743 association studies. *Int. J. Immunogenet.* 35, 179–192.

744

745 Venter, J.C., Adams, M.D., Myers, E.W., Li, P.W., Mural, R.J., Sutton, G.G., Smith,
746 H.O., Yandell, M., Evans, C.A., Holt, R.A., et al., 2001. The sequence of the
747 human genome. *Science* 291, 1304–1351.

748

- 749 WHO, 1973. Report of the international pilot study of schizophrenia.
750
- 751 Winternitz, J., Abbate, J., Huchard, E., Havl'ivcek, J., Garamszegi, L., 2017.
752 Patterns of MHC-dependent mate selection in humans and nonhuman primates: a
753 meta-analysis. *Molecular ecology* 26, 668–688.
754
- 755 Wood, A.R., Esko, T., Yang, J., Vedantam, S., Pers, T.H., Gustafsson, S., Chu, A.Y.,
756 Estrada, K., Luan, J., Kutalik, Z., et al., 2014. Defining the role of common
757 variation in the genomic and biological architecture of adult human height. *Nature*
758 *Genet* 46, 1173–1186.
759
- 760 Xu, K., Schadt, E.E., Pollard, K.S., Roussos, P., Dudley, J.T., 2015. Genomic and
761 network patterns of schizophrenia genetic variation in human evolutionary
762 accelerated regions. *Mol Biol Evol* 32, 1148–1160.
763
764
- 765
- 766
- 767

768 **Figure legends**

769 **Fig. 1: Enrichment plots of hypo-DMR and hyper-DMR SNPs in schizophrenia**

770 Quantile-quantile (QQ) plots of GWAS SNPs for Schizophrenia (SCZ) with the
771 extended MHC region (chr6: 25-35Mb) unmasked (A) and masked (B). Expected -
772 $\log_{10} p$ -values under the null hypothesis are shown on the X-axis. Observed $-\log_{10} p$ -
773 values are on the Y-axis. The values for all GWAS SNPs are plotted in dark green
774 while the values for SNPs in linkage disequilibrium (LD) with hypo-methylated
775 DMRs are plotted in blue and SNPs in LD with hyper-methylated DMRs are plotted
776 in pink. A leftward deflection of the plotted p -values from the line for all GWAS
777 SNPs indicates enrichment of true signals – the greater the leftward deflection, the
778 stronger the enrichment. Genomic correction was performed on all SNPs with global
779 lambda.

780

781 **Fig. 2: Enrichment plots of hypo-DMR and hyper-DMR SNPs across**
782 **multiple traits**

783 Thirteen different GWASs were analysed using a common set of ~2.4 million
784 SNPs. The p -values for the common set of GWAS SNPs are plotted in dark
785 green; p -values for SNPs that tag hypo-methylated DMRs are plotted in blue;
786 and p -values for SNPs that tag hyper-methylated DMRs are plotted in pink.
787 ADHD, attention deficit hyperactivity disorder; BMI, body mass index; BPD,
788 bipolar disorder; DBP, diastolic blood pressure; HDL, high density lipoprotein;
789 LDL, low density lipoprotein; RA, rheumatoid arthritis; SBP, systolic blood
790 pressure; SCZ, schizophrenia; TC, total cholesterol; TG, triglycerides. The
791 MHC region was absent from the common set of SNPs.

792

793 **Fig. 3: INRICH test for enrichment of association of DMR gene sets and NSS**

794 **genes with SCZ, MHC masked**

795 A visual heatmap depicting *p*-values from bootstrapping with 5,000 iterations. The
796 various evolutionary annotations compared are as follows. HypoDMR – human hypo-
797 methylated DMRs; HyperDMR – human hyper-methylated DMRs. HypoDMR and
798 HyperDMR were taken from the study by Hernando-Herraez et al. (2013). dmrH –
799 human-specific DMRs (Gokhman et al, 2014), which are referred to as non-primate
800 DMRs in this manuscript. NSS - Neanderthal selective sweep. Datasets marked with *
801 have been previously reported by Banerjee et al. (2017) and are presented here for
802 comparison only.

803

804

Figure 1




Figure 2




Figure 3

